Surgery Group Los Angeles, Los Angeles, CA, USA.
Surgery Department, Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil.
Tech Coloproctol. 2024 Jan 31;28(1):29. doi: 10.1007/s10151-023-02881-4.
Liposome bupivacaine (LB) is a long-acting anesthetic to enhance postoperative analgesia. Studies evaluating the efficacy of the LB against an active comparator (bupivacaine or placebo) on acute postoperative pain control in hemorrhoidectomy procedures are few and heterogeneous. Therefore, we performed a systematic review and meta-analysis comparing LB's analgesic efficacy and side effects to conventional/placebo anesthetic in hemorrhoidectomy patients.
We performed a systematic review and meta-analysis of randomised controlled trials investigating the use of LB after haemorrhoidectomy. We searched the literature published from the time of inception of the datasets to August 19, 2022. The electronic databases included English publications in Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, and Scopus.
A total of 338 patients who underwent a hemorrhoidectomy procedure enrolled in three randomized clinical trials were included. The overall mean age was 45.84 years (SD ± 11.43), and there was a male predominance (53.55% male). In total 194 patients (52.2%) received LB and 144 (47.8%) received either bupivacaine or placebo. Pain scores at 72 h in the LB (199, 266, and 300 mg) were significantly lower than in the bupivacaine HCl group (p = 0.002). Compared to the bupivacaine/placebo group, the time to first use of opioids in the LB group was significantly longer at LB 199 mg (11 h vs. 9 h), LB 266 mg (19 h vs. 9 h), and LB 300 mg (19 h vs. 8 h) (p < 0.05). Moreover, compared to the bupivacaine/epinephrine group, it was significantly lower in the LB 266 mg group (3.7 vs. 10.2 mg) and at LB 300 mg (13 vs. 33 mg) (p < 0.05). Finally, regarding adverse effects, the conventional anesthetic/placebo group reported more pain in bowel movement than LB groups (OR 2.60, 95% CI 1.31-5.16).
Comparing LB to conventional anesthetic/placebo anesthetic for hemorrhoidectomy, we found a statistically significant reduction in pain through 72 h, decreased opioid requirements, and delayed time to first opioid use. Moreover, the conventional anesthetic/placebo group reported more pain in bowel movement than LB groups.
脂质体布比卡因 (LB) 是一种长效麻醉剂,可增强术后镇痛效果。评估 LB 对急性痔切除术术后疼痛控制效果的研究与活性对照(布比卡因或安慰剂)相比较少且存在异质性。因此,我们进行了一项系统评价和荟萃分析,比较 LB 与常规/安慰剂麻醉剂在痔切除术患者中的镇痛效果和副作用。
我们对评估 LB 在痔切除术后使用的随机对照试验进行了系统评价和荟萃分析。我们检索了从数据集创建到 2022 年 8 月 19 日发表的文献。电子数据库包括在 Ovid MEDLINE 处理中及其他非索引引文、Ovid MEDLINE、Ovid EMBASE 和 Scopus 中发表的英文文献。
共有 338 名接受痔切除术的患者纳入了三项随机临床试验。总体平均年龄为 45.84 岁(标准差±11.43),男性占优势(53.55%男性)。共有 194 名患者(52.2%)接受 LB 治疗,144 名患者(47.8%)接受布比卡因或安慰剂治疗。LB(199、266 和 300mg)组在 72 小时的疼痛评分明显低于布比卡因盐酸盐组(p=0.002)。与布比卡因/安慰剂组相比,LB 199mg(11 小时比 9 小时)、LB 266mg(19 小时比 9 小时)和 LB 300mg(19 小时比 8 小时)组首次使用阿片类药物的时间明显延长(p<0.05)。此外,与布比卡因/肾上腺素组相比,LB 266mg 组(3.7 毫克比 10.2 毫克)和 LB 300mg 组(13 毫克比 33 毫克)的疼痛明显更低(p<0.05)。最后,关于不良反应,常规麻醉/安慰剂组报告的排便疼痛比 LB 组更多(OR 2.60,95%CI 1.31-5.16)。
与常规麻醉/安慰剂麻醉相比,我们发现 LB 可显著降低痔切除术 72 小时内的疼痛、减少阿片类药物的需求,并延迟首次使用阿片类药物的时间。此外,常规麻醉/安慰剂组报告的排便疼痛比 LB 组更多。